Company | Page 59 of 71 | SpiritIndia.com

Flu :: Cognis Targets Cold, Flu Season with Arsenal of Immunity-Enhancing Ingredients

A compromised immune system makes people more prone to contracting a cold or flu, and Cognis is helping companies meet the growing demand worldwide for immunity boosting dietary supplements and functional foods. Colds and flu are the most frequent infections across all age groups. Each year, Americans suffer from one billion colds, 100,000 are hospitalized and about 36,000 die from the flu and its complications. Immune health is also a global concern with frequent colds and flu ranked as one of the top three health problems by consumers in China, India and Latin America.

Nutrition :: Cognis to launch Omevital, omega-3 fatty acids at HiE

Cognis will unveil its new range of high quality omega-3 fish oil products at this year?s Health Ingredients Europe event in Frankfurt. Under the brand name Omevital?, and available in ethyl ester and triglyceride forms, the new range of marine-origin oils delivers products of outstanding quality and purity, ultra-refined through state-of-the-art manufacturing processes, in accordance with Pharma GMP standards.

Biofuel :: Broin and Novozymes to collaborate on development of ethanol from cellulosic biomass

Two leading players within the growing biofuels industry, Broin and Novozymes, announced a collaboration to take the next steps needed to bring cost-effective ethanol derived from corn stover to market. The collaboration is an extension of the close partnership between the two companies and is a great opportunity for Novozymes to put its unique biotechnology platform at work and for Broin to aim at a fast commercialization.

Health :: ORIDIS Biomed Licenses NIH’s Proprietary Tissue Micro-Array Technology

ORIDIS Biomed, a biopharmaceutical company announced that it has entered into a license agreement with the National Institutes of Health (NIH) for the worldwide commercial use of NIH’s proprietary Tissue Micro-Array (TMA) technology.

Hepatitis :: PEG-INTRON, peginterferon and REBETOL, ribavirin in Hepatitis C — Schering-Plough

Schering-Plough reported data from EPIC3, a large ongoing clinical study, showing that retreatment with PEG-INTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy can result in sustained virologic response(1) (SVR) in patients with chronic hepatitis C who failed previous treatment with any alpha interferon-based combination therapy, including peginterferon regimens. In this study, 56 percent of patients who had undetectable virus (HCV-RNA) after 12 weeks went on to achieve SVR with a 48-week course of therapy. Of the first 1,354 patients retreated, approximately 38 percent had undetectable virus at week 12. Importantly, patients who did not have undetectable virus at 12 weeks had little chance of achieving SVR. Overall, 23 percent of patients achieved SVR.

ADHD :: Lilly’s Strattera, atomoxetine effective in treating ADHD in children and adolescents

New data suggest that Strattera? (atomoxetine HCl) improved ADHD symptoms in children and adolescents who had both ADHD and a reading disorder, like dyslexia. Results were announced at a meeting of child and adolescent psychiatrists.

Diabetes :: EC approves use of insulin drug “NovoRapid”

There is new hope of succour for women suffering from pregnancy diabetes with the European Commission (EC) approving the use of insulin drug ”NovolRapid,” as the first modern insulin that has a label stating can be used in pregnancy.

ADHD :: Daytrana, methylphenidate transdermal system provides individualized ADHD symptom management

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch, DAYTRANA tm (methylphenidate transdermal system), has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when the ADHD patch is taken off earlier than the recommended nine hours. The ability to remove the patch earlier than the recommended nine-hour wear time allows physicians the opportunity to manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping. These phase IIIb clinical trial results were reported today at a major scientific and educational meeting of child and adolescent psychiatrists in San Diego, Calif.

Health :: UWM brain research supports drug development from jellyfish protein

With the research support from the University of Wisconsin-Milwaukee, a Wisconsin biotech company has found that a compound from a protein found in jellyfish is neuro-protective and may be effective in treating neurodegenerative diseases.

ADHD :: Lisdexamfetamine dimesylate in ADHD phase 3 data presented

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that their investigational ADHD treatment, lisdexamfetamine dimesylate (also known as NRP104 or LDX), yielded a 60 percent improvement in the primary rating scale scores for symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 years who received six months of treatment in an open-label phase III study. Results also demonstrated that at 6 months, 95 percent of children taking lisdexamfetamine dimesylate (NRP104/LDX) produced a “much improved” or “very much improved” rating on the Clinical Global Impressions ? Improvement score. These results were presented last weekend at a national meeting of child and adolescent psychiatrists.